Mehrnoosh Shanaki

Mehrnoosh Shanaki

Auto-generated profile, based on publicly available information

Mehrnoosh Shanaki

Department of Medical Laboratory Sciences, School of Allied Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016
Verified
Journal Article
Open access
NMNaser Mobarra
Naser Mobarra
MSMehrnoosh Shanaki
Mehrnoosh Shanaki
HEHassan Ehteram
Hassan Ehteram
HNHajar Nasiri
Hajar Nasiri
MSMehdi Sahmani
Mehdi Sahmani
MAMehdi Azad
Mehdi Azad
Iron chelation therapy is used to reduce iron overload development due to its deposition in various organs such as liver and heart after regular transfusion. In this review, different iron chelators implicated in treatment of iron overload in various clinical conditions have been evaluated using more up-to-date studies focusing on these therapeutic agents. Deferoxamine, Deferiprone and Deferasirox are the most important specific US FDA-approved iron chelators. Each of these chelators has their own advantages and disadvantages, various target diseases, levels of deposited iron and clinical symptoms of the afflicted patients which may affect their selection as the best modality. Taken together, in many clinical disorders, choosing a standard chelator does not have an accurate index which requires further clarifications. The aim of this review is to introduce and compare the different iron chelators regarding their advantages and disadvantages, usage dose and specific applications.

1 January 2018 in Obesity Research & Clinical Practice
Verified
Journal Article
Closed access
PGParvin Ghareghani
Parvin Ghareghani
MSMehrnoosh Shanaki
Mehrnoosh Shanaki
SASaeideh Ahmadi
Saeideh Ahmadi
AKAli Reza Khoshdel
Ali Reza Khoshdel
NRNeda Rezvan
Neda Rezvan
SGSattar Gorgani-Firuzjaee
Sattar Gorgani-Firuzjaee

1 November 2017 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
MSMehrnoosh Shanaki
Mehrnoosh Shanaki
NMNariman Moradi
Nariman Moradi
SESolaleh Emamgholipour
Solaleh Emamgholipour
RFReza Fadaei
Reza Fadaei
HPHossein Poustchi
Hossein Poustchi

13 October 2018 in Archives of Physiology and Biochemistry
Verified
Journal Article
Closed access
FKFatemeh Kalaki-Jouybari
Fatemeh Kalaki-Jouybari
MSMehrnoosh Shanaki
Mehrnoosh Shanaki
MDMaryam Delfan
Maryam Delfan
SGSattar Gorgani-Firuzjaee
Sattar Gorgani-Firuzjaee
SKSoheyla Khakdan
Soheyla Khakdan
Background: Exercise intervention is strongly recommended to manage metabolic diseases. In this study, we investigate, whether HIIT and CET can induce hepatic miR-122 expression, NAFLD rats with diabetes. Methods: 40 Wistar rats divided into 2 groups, non-diabetic (NDC) and diabetic .Type 2 diabetes was induced by high-fat high-fructose diet (HFHFD). Then diabetic rats were subdivided into three groups: diabetic control (HFHFD + DC), CET (HFHFD + CET), and HIIT (HFHFD + HIIT). After eight weeks of exercise on a rodent treadmill, we measured miR-122 and its target genes expression in the liver of rats. Results: HIIT decreased the expression of FAS, ACC, SREBP-1c compared with HFHFD + DC (p = .004, p = .032, p = .043, respectively), and could partially increase miR-122 expression as compared with HFHFD + DC (26.8%, p = .68). Conclusions: Exercise training could be a non-pharmacological intervention for improvement of NAFLD of diabetic rats by induction of miR-122. HIIT had a greater effect on NAFLD amelioration than CET.

9 December 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMehrnoosh Shanaki
Mehrnoosh Shanaki
RFReza Fadaei
Reza Fadaei
NMNariman Moradi
Nariman Moradi
SESolaleh Emamgholipour
Solaleh Emamgholipour
HPHossein Poustchi
Hossein Poustchi
Numerous studies have shown that C1q/TNF-related proteins (CTRPs) are involved in the pathophysiology of metabolic disorders, such as Non-alcoholic fatty liver disease (NAFLD) and Type 2 Diabetes (T2DM). There is a little information concerning CTRP13 in the context of NAFLD and T2DM. We evaluated the plasma levels of CTRP13 in healthy control and patients with NAFLD, T2DM and NAFLD+T2DM, and also correlations between CTRP13 plasma levels and clinical and subclinical features. Circulating CTRP13 was examined in 88 male (20 healthy control, 22 T2DM patients, 22 NAFLD patients and 22 NAFLD+T2DM patients). CTRP13 and adiponectin plasma levels were measured by ELISA method. CTRP13 serum levels were higher in the control group than the other groups (all p <0.001). CTRP13 had significant negative correlation with unfavorable anthropometric and metabolic factors including BMI, visceral fat, Insulin, HOMA-IR, TG, AST, ALT and ɣ-GT and have a positive correlation with plasma concentration of adiponectin. CTRP13 had a significant inverse correlation with cIMT (r = -0.345) and liver stiffness (LS) (r = -0.372) (both, p <0.001). Also, the multiple stepwise linear regression has shown that visceral fat is a significant predictor of CTRP13 serum levels (p <0.001). Multiple stepwise linear regression with LS as the dependent variable showed that ALT (p < 0.001) and SBP (p = 0.010) were two predictor factors for LS. Strikingly, multiple stepwise linear regression showed that CTRP13 (p = 0.006) and SBP (p = 0.007) were two independent predictors for cIMT. Lower CTRP13 in patients with T2DM, NAFLD and NAFLD + T2DM was associated with increased risk of the diseases. CTRP13 have negative associations with unfavorable metabolic factors and also is a negative predictor of cIMT. Our results suggested that CTRP13 could be an associated factor with NAFLD in patients with and without T2DM.

22 February 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
JDJavad Daneshmoghadam
Javad Daneshmoghadam
AOAbolfazl Omidifar
Abolfazl Omidifar
NDNader Akbari Dilmaghani
Nader Akbari Dilmaghani
ZKZahereh Karimi
Zahereh Karimi
SESolaleh Emamgholipour
Solaleh Emamgholipour
MSMehrnoosh Shanaki
Mehrnoosh Shanaki
Background: There is evidence regarding the role of two lncRNAs: MEG3 and H19 the pathomechanism of obesity and related disorders. Here, we aimed to evaluate the expression of MEG3 and H19 in visceral adipose tissues (VAT) and subcutaneous adipose tissues (SAT) of obese women (n = 18), as compared to normal‐weight women (n = 17). Moreover, we sought to identify the association of expression of MEG3 and H19 in SAT and VAT with obesity parameters, insulin resistance, and the mRNA expression of possible target genes involved in adipogenesis and lipogenesis including peroxisome proliferator‐activated receptor gamma (PPARγ), fatty acid synthase (FAS), and acetyl‐CoA carboxylase (ACC).Methods: Real‐time PCR was performed to investigate the mRNA expression of the above‐mentioned genes in VAT and SAT from all participants.Results: The results showed lower mRNA levels of H19 in SAT of obese women, compared to normal‐weight women, while MEG3 expression was significantly higher in the SAT of the obese group rather than controls. Correlation analysis indicated that the transcript level of H19 had an inverse correlation with obesity indices and HOMA‐IR values. However, MEG3 expression displayed a positive correlation with all the indicated parameters in all participants. Interestingly, a positive correlation was found between transcript level of MEG3 in SAT with FAS and PPARγ. However, there was an inverse correlation between SAT expression of H19 and FAS.Conclusions: It appears that lncRNAs, MEG3 and H19, are involved in obesity‐related conditions. However, more clinical studies are still required to clarify the relationships between lncRNAs with obesity and related abnormalities.